The bispecific antibody market was valued at $5.50 billion in 2022 and is estimated to reach $109.37 billion by 2032, exhibiting a CAGR of 34.8% from 2023 to 2032.
A bispecific antibody, known as bsAb, is an artificial antibody molecule that is engineered for attachment of two separate target antigens at the same time. Traditional antibodies are generally monospecific, which means they are expected to attach to one antigen only. On the other hand, bispecific antibodies have two antigen-binding sites, permitting them to recognize and attach to two distinct targets. The clinical therapeutic effects of BsAbs are superior to those of monoclonal antibodies (MoAbs), with broad applications for tumor immunotherapy and for the treatment of other diseases cancer, inflammation, viral infection, and autoimmune diseases.
The bispecific antibody market growth is driven by high prevalence rate of cancer as well as auto-immune diseases and advancement in biotechnology and antibody engineering for development of bispecific antibody. In addition, bispecific antibodies have gained attention in the field of oncology. Bispecific antibodies are expected to simultaneously bind to tumor-specific antigens on cancer cells and immune cells, such as T cells. Rise in prevalence of cancer, infectious diseases, and auto-immune diseases are anticipated to drive the growth of the market. For instance, according to American cancer Society, in 2022, estimated number of new cancer cases in the U.S. were around 1,918,030.
Moreover, Bispecific antibodies (bsAbs), with binding specificity for two different target molecules, have recently been developed for a range of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and psoriasis, and tested in clinical trials. Thus, rise in prevalence of autoimmune diseases is anticipated to drive the growth of the market during the forecast period. In addition, rise in demand for bispecific antibodies and high response rate for bispecific antibodies in multiple myeloma drives the growth of the market. For instance, according to American Society of Clinical Oncology (ASCO), in 2023, an estimated 35,730 adults (19,860 men and 15,870 women) in the U.S. are expected to be diagnosed with multiple myeloma. As per the same source, an estimated 176,404 people were diagnosed with multiple myeloma in 2020 globally.
Moreover, rise in effectiveness of the bispecific antibody in multiple myeloma boosts the growth of the market. For instance, according to American Association for Cancer Research, in 2023, the patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate.
Moreover, increase in prevalence of breast cancer and rise in demand for bispecific antibodies in treatment of breast cancer is anticipated to drive the growth of the market. For instance, according to the American Cancer Society, in January 2022, an estimated 287,850 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S., along with 51,400 new cases of non-invasive breast cancer. As per the same source, in 2022, there were more than 3.8 million women with a history of breast cancer in the U.S. In addition, rise in effectiveness of bispecific antibodies in breast cancer treatment drives the growth of the market. For instance, triple negative breast cancer (TNBC) is a kind of breast cancer with a poor prognosis and few treatment options. In October 2021, according to National Library of Medicine, researchers tested the anticancer activity of F7AK3, a bispecific antibody that binds both trophoblast cell surface antigen 2 (TROP2) and CD3 to identify innovative and effective therapeutics for TNBC. Thus, rise in R&D for development of bispecific antibodies is anticipated to boost the market growth.
On the other hand, side effects associated with bispecific antibodies such as cytokine release syndrome, infusion-related reactions, organ toxicity, hematological effects, immunogenicity, and others are anticipated to hamper the growth of the market. Moreover, complex manufacturing processes and regulatory challenges are expected to restrain the growth of the market.
However, increase in demand for medical services in developed countries such as the U.S., Canada, and Germany and growth opportunities in emerging markets are expected to create immense growth opportunities for the bispecific antibody market during the forecast period.
The bispecific antibody market is segmented on the basis of product, application, end user, and region. On the basis of product, the market is categorized into blinatumomab, emicizumab, and others. Others subsegment includes elranatamab, mosunetuzumab, glofitamab, and zenocutuzumab. On the basis of application, the market is divided into cancer, hemophilia, and others. Others subsegment includes autoimmune diseases, neovascular age-related macular degeneration, and Alzheimer disease. On the basis of end user, the market is divided into hospitals, cancer center, and others. Others subsegment includes research centers and academic institutions.
On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Major key players that operate in the global bispecific antibody market are AbbVie, Pfizer, Portola Pharmaceuticals, Innovent bio, Merus, MacroGenics, Genmab A/S, AstraZeneca, NovImmune S.A., Regeneron Pharmaceuticals, F. Hoffmann-La Roche Ltd., Johnson & Johnson. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand the bispecific antibody market share.
A bispecific antibody, known as bsAb, is an artificial antibody molecule that is engineered for attachment of two separate target antigens at the same time. Traditional antibodies are generally monospecific, which means they are expected to attach to one antigen only. On the other hand, bispecific antibodies have two antigen-binding sites, permitting them to recognize and attach to two distinct targets. The clinical therapeutic effects of BsAbs are superior to those of monoclonal antibodies (MoAbs), with broad applications for tumor immunotherapy and for the treatment of other diseases cancer, inflammation, viral infection, and autoimmune diseases.
The bispecific antibody market growth is driven by high prevalence rate of cancer as well as auto-immune diseases and advancement in biotechnology and antibody engineering for development of bispecific antibody. In addition, bispecific antibodies have gained attention in the field of oncology. Bispecific antibodies are expected to simultaneously bind to tumor-specific antigens on cancer cells and immune cells, such as T cells. Rise in prevalence of cancer, infectious diseases, and auto-immune diseases are anticipated to drive the growth of the market. For instance, according to American cancer Society, in 2022, estimated number of new cancer cases in the U.S. were around 1,918,030.
Moreover, Bispecific antibodies (bsAbs), with binding specificity for two different target molecules, have recently been developed for a range of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and psoriasis, and tested in clinical trials. Thus, rise in prevalence of autoimmune diseases is anticipated to drive the growth of the market during the forecast period. In addition, rise in demand for bispecific antibodies and high response rate for bispecific antibodies in multiple myeloma drives the growth of the market. For instance, according to American Society of Clinical Oncology (ASCO), in 2023, an estimated 35,730 adults (19,860 men and 15,870 women) in the U.S. are expected to be diagnosed with multiple myeloma. As per the same source, an estimated 176,404 people were diagnosed with multiple myeloma in 2020 globally.
Moreover, rise in effectiveness of the bispecific antibody in multiple myeloma boosts the growth of the market. For instance, according to American Association for Cancer Research, in 2023, the patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate.
Moreover, increase in prevalence of breast cancer and rise in demand for bispecific antibodies in treatment of breast cancer is anticipated to drive the growth of the market. For instance, according to the American Cancer Society, in January 2022, an estimated 287,850 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S., along with 51,400 new cases of non-invasive breast cancer. As per the same source, in 2022, there were more than 3.8 million women with a history of breast cancer in the U.S. In addition, rise in effectiveness of bispecific antibodies in breast cancer treatment drives the growth of the market. For instance, triple negative breast cancer (TNBC) is a kind of breast cancer with a poor prognosis and few treatment options. In October 2021, according to National Library of Medicine, researchers tested the anticancer activity of F7AK3, a bispecific antibody that binds both trophoblast cell surface antigen 2 (TROP2) and CD3 to identify innovative and effective therapeutics for TNBC. Thus, rise in R&D for development of bispecific antibodies is anticipated to boost the market growth.
On the other hand, side effects associated with bispecific antibodies such as cytokine release syndrome, infusion-related reactions, organ toxicity, hematological effects, immunogenicity, and others are anticipated to hamper the growth of the market. Moreover, complex manufacturing processes and regulatory challenges are expected to restrain the growth of the market.
However, increase in demand for medical services in developed countries such as the U.S., Canada, and Germany and growth opportunities in emerging markets are expected to create immense growth opportunities for the bispecific antibody market during the forecast period.
The bispecific antibody market is segmented on the basis of product, application, end user, and region. On the basis of product, the market is categorized into blinatumomab, emicizumab, and others. Others subsegment includes elranatamab, mosunetuzumab, glofitamab, and zenocutuzumab. On the basis of application, the market is divided into cancer, hemophilia, and others. Others subsegment includes autoimmune diseases, neovascular age-related macular degeneration, and Alzheimer disease. On the basis of end user, the market is divided into hospitals, cancer center, and others. Others subsegment includes research centers and academic institutions.
On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Major key players that operate in the global bispecific antibody market are AbbVie, Pfizer, Portola Pharmaceuticals, Innovent bio, Merus, MacroGenics, Genmab A/S, AstraZeneca, NovImmune S.A., Regeneron Pharmaceuticals, F. Hoffmann-La Roche Ltd., Johnson & Johnson. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand the bispecific antibody market share.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the bispecific antibody market analysis from 2022 to 2032 to identify the prevailing bispecific antibody market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the bispecific antibody market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global bispecific antibody market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly update (only available with the purchase of an enterprise license)
- 5 additional company profiles of your choice, pre- or post-purchase, as a free update.
- Free updated version (once released) with the purchase of a 1-5 or enterprise user license.
- 16 analyst hours of support (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% free customization (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
- Free data pack (Excel version) with the purchase of a 1-5 or enterprise user license.
- Free report update, if the report is 6-12 months old or older.
- 24-hour priority response
- Free industry updates and white papers.
Key Market Segments
By Applications
- Others
- Cancer
- Hemophilia
By End User
- Hospitals
- Cancer Center
- Others
By Product
- Blinatumomab
- Emicizumab
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East
- Africa
Key Market Players
- MacroGenics Inc.
- AstraZeneca plc
- Regeneron Pharmaceuticals, Inc.
- Johnson & Johnson
- Pfizer Ltd
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Amgen Inc.
- Merus
- AbbVie Inc
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: BISPECIFIC ANTIBODY MARKET, BY PRODUCT
CHAPTER 5: BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS
CHAPTER 6: BISPECIFIC ANTIBODY MARKET, BY END USER
CHAPTER 7: BISPECIFIC ANTIBODY MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to this report, the bispecific antibody market was valued at $5.5 billion in 2022, and is estimated to reach $109.4 billion by 2032, growing at a CAGR of 34.8% from 2023 to 2032.Bispecific antibodies bind to two different epitopes, or antigens at the same time. This dual action principle makes bispecific antibodies an interesting approach to improving target specificity by binding two antigens on the same cell. They are created by combining the binding regions of two different antibodies or by engineering a single antibody with two specificities. This is achieved through various methods, such as genetic engineering, hybridoma technology, or protein engineering techniques. Bispecific antibodies offer an unprecedented combination of precision, stability and diverse targeting ability that have the potential to revolutionize the way we treat serious diseases.
There are several types of bispecific antibodies such as blinatumomab, emicizumab, and others. Others include elranatamab, mosunetuzumab, glofitamab, and zenocutuzumab. Applications of bispecific antibodies include cancer, hemophilia, and others. Others includes autoimmune diseases, neovascular age-related macular degeneration, and Alzheimer’s disease. End users of bispecific antibodies are hospitals, cancer center, and others. Others include clinic, hemophilia treatment center.
Key factors driving the growth of the bispecific antibody market include rise in prevalence of chronic diseases, increase in number of product approvals for bispecific antibody and rise in the research and development activities. Moreover, increase in number of strategic collaborations and partnerships in bispecific antibody market is anticipated to boost the growth of the market. For instance, in January 2022, ABL, a leading biotech research company of the world, announced the collaboration with SANOFI SA, a multinational pharmaceutical and healthcare company. This collaboration aims for the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson’s disease is expected to boost the growth of the market.
In addition, in September 2022, Abpro, a biotech company, finalized strategic partnership with Celltrion, a biopharmaceutical company for global development and commercialization of a cancer treatment bispecific antibody. Moreover, in December 2022, Akeso Inc., a biopharmaceutical company, announces collaboration and license agreement for up to $5 billion with Summit therapeutics, a biopharmaceutical company to accelerate global development and commercialization of its breakthrough bispecific antibody, Ivonescimab (PD-1/VEGF). Thus, rise in the number of strategic collaborations and partnerships is anticipated to increase the development of bispecific antibodies and boost the growth of the bispecific antibody market. Moreover, increase in prevalence of hemophilia, rise in awareness among the population regarding treatment of hemophilia and high presence of market players who manufactures bispecific antibody drives the growth of market.
The bispecific antibody market is segmented on the basis of product, application, end user, and region. On the basis of product, the bispecific antibody market is categorized into blinatumomab, emicizumab, and others. Others subsegment includes elranatamab, mosunetuzumab, glofitamab, and zenocutuzumab. On the basis of application, the bispecific antibody market is divided into cancer, hemophilia, and others. Others subsegment includes autoimmune diseases, neovascular age-related macular degeneration, and Alzheimer disease. On the basis of end user, the bispecific antibody market is divided into hospitals, cancer center, and others. Others subsegment includes research centers and academic institutions.
Region-wise, the market is analyzed across North America (U. S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The key players profiled in the study include AbbVie, Pfizer, Portola Pharmaceuticals, Innovent bio, Merus, MacroGenics, Genmab A/S, AstraZeneca, NovImmune S. A., Regeneron Pharmaceuticals, F. Hoffmann-La Roche Ltd., Johnson & Johnson. The players in the market have been actively engaged in the adoption various strategies such as acquisition, product launch and expansion to remain competitive and gain advantage over the competitors in the market. For instance, in April 2023, Lonza, a global pharmaceutical, biotech, and nutrition company announced an agreement with ABL Bio, the leading biotech research company of the world focusing on bispecific antibodies for immuno-oncology and neurodegenerative diseases. The collaboration is intended to help in the development and manufacturing of new bispecific antibody product of the company.
Key Market Insights
By product, emicizumab segment was the highest revenue contributor to the market and is estimated to reach $81.15 billion by 2032, with a CAGR of 34.4%.By application, the hemophilia will reach to $87.94 billion by 2032 segment dominated the global market. However, the cancer segment is expected to be the fastest-growing segment with a CAGR of 35.6% during the forecast period.
By end user, the hospitals segment dominated the global market. However, the cancer center segment is expected to be the fastest-growing segment with a CAGR of 35.3% during the forecast period.
Based on region, North America garnered the largest revenue share in 2022, whereas Asia-pacific is anticipated to grow at the highest CAGR of 36.4% during the forecast period
Companies Mentioned
- MacroGenics Inc.
- AstraZeneca plc
- Regeneron Pharmaceuticals, Inc.
- Johnson & Johnson
- Pfizer Ltd
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Amgen Inc.
- Merus
- AbbVie Inc
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
